Hormone-refractory Breast Cancer

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2020-07-13
Clinical Trial Update: Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery [Phase 2]
Phase 2 trial evaluating pembrolizumab with capecitabine for locally advanced or metastatic triple-negative breast cancer or hormone-refract…